Bone Other Operating Expenses vs Depreciation And Amortization Analysis

BBLGW Stock  USD 28.49  3.29  10.35%   
Bone Biologics financial indicator trend analysis is way more than just evaluating Bone Biologics Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bone Biologics Corp is a good investment. Please check the relationship between Bone Biologics Other Operating Expenses and its Depreciation And Amortization accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Other Operating Expenses vs Depreciation And Amortization

Other Operating Expenses vs Depreciation And Amortization Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bone Biologics Corp Other Operating Expenses account and Depreciation And Amortization. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Bone Biologics' Other Operating Expenses and Depreciation And Amortization is 0.4. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Depreciation And Amortization in the same time period over historical financial statements of Bone Biologics Corp, assuming nothing else is changed. The correlation between historical values of Bone Biologics' Other Operating Expenses and Depreciation And Amortization is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Bone Biologics Corp are associated (or correlated) with its Depreciation And Amortization. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation And Amortization has no effect on the direction of Other Operating Expenses i.e., Bone Biologics' Other Operating Expenses and Depreciation And Amortization go up and down completely randomly.

Correlation Coefficient

0.4
Relationship DirectionPositive 
Relationship StrengthWeak

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bone Biologics Corp. It is also known as Bone Biologics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.
Most indicators from Bone Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Selling General Administrative is likely to drop to about 2 M in 2024. Tax Provision is likely to drop to 2,078 in 2024
 2022 2023 2024 (projected)
Tax Provision3.2K3.7K2.1K
Interest Expense2.2M2.0M1.5M

Bone Biologics fundamental ratios Correlations

-0.39-0.21-0.36-0.42-0.39-0.39-0.340.240.67-0.63-0.51-0.56-0.74-0.39-0.37-0.2-0.61-0.080.7-0.52-0.44-0.230.03-0.370.21
-0.39-0.650.990.761.00.33-0.110.62-0.450.59-0.25-0.070.550.67-0.31-0.270.35-0.57-0.330.380.440.90.610.49-0.58
-0.21-0.65-0.68-0.34-0.660.120.56-0.99-0.02-0.120.890.730.08-0.430.820.340.210.81-0.210.01-0.15-0.8-0.78-0.280.7
-0.360.99-0.680.780.990.27-0.120.64-0.470.62-0.29-0.110.550.7-0.29-0.290.4-0.57-0.340.430.480.940.610.51-0.59
-0.420.76-0.340.780.760.330.390.28-0.570.660.040.050.660.920.060.190.55-0.16-0.440.550.590.640.080.64-0.38
-0.391.0-0.660.990.760.33-0.110.62-0.450.59-0.25-0.070.550.67-0.31-0.270.35-0.57-0.330.380.440.90.610.49-0.58
-0.390.330.120.270.330.330.28-0.22-0.290.310.440.570.330.20.120.00.380.19-0.570.090.030.12-0.020.030.15
-0.34-0.110.56-0.120.39-0.110.28-0.6-0.320.240.680.460.380.280.620.520.420.31-0.360.30.31-0.31-0.840.070.3
0.240.62-0.990.640.280.62-0.22-0.60.070.06-0.92-0.77-0.130.37-0.83-0.36-0.27-0.820.29-0.050.120.770.780.25-0.7
0.67-0.45-0.02-0.47-0.57-0.45-0.29-0.320.07-0.96-0.35-0.33-0.93-0.71-0.37-0.3-0.870.050.88-0.91-0.83-0.46-0.02-0.760.53
-0.630.59-0.120.620.660.590.310.240.06-0.960.230.260.930.740.280.220.86-0.14-0.840.910.860.610.140.79-0.54
-0.51-0.250.89-0.290.04-0.250.440.68-0.92-0.350.230.910.45-0.090.860.320.520.72-0.540.270.09-0.49-0.65-0.040.53
-0.56-0.070.73-0.110.05-0.070.570.46-0.77-0.330.260.910.43-0.120.70.180.530.6-0.610.21-0.08-0.3-0.38-0.170.48
-0.740.550.080.550.660.550.330.38-0.13-0.930.930.450.430.690.420.290.820.03-0.820.840.810.440.010.76-0.42
-0.390.67-0.430.70.920.670.20.280.37-0.710.74-0.09-0.120.69-0.050.330.55-0.25-0.50.650.720.660.150.8-0.65
-0.37-0.310.82-0.290.06-0.310.120.62-0.83-0.370.280.860.70.42-0.050.210.630.69-0.430.490.24-0.42-0.680.060.52
-0.2-0.270.34-0.290.19-0.270.00.52-0.36-0.30.220.320.180.290.330.210.120.33-0.260.220.23-0.33-0.530.3-0.13
-0.610.350.210.40.550.350.380.42-0.27-0.870.860.520.530.820.550.630.120.17-0.880.890.680.35-0.140.53-0.14
-0.08-0.570.81-0.57-0.16-0.570.190.31-0.820.05-0.140.720.60.03-0.250.690.330.17-0.14-0.03-0.22-0.69-0.55-0.10.69
0.7-0.33-0.21-0.34-0.44-0.33-0.57-0.360.290.88-0.84-0.54-0.61-0.82-0.5-0.43-0.26-0.88-0.14-0.73-0.59-0.310.06-0.50.25
-0.520.380.010.430.550.380.090.3-0.05-0.910.910.270.210.840.650.490.220.89-0.03-0.730.860.44-0.050.75-0.42
-0.440.44-0.150.480.590.440.030.310.12-0.830.860.09-0.080.810.720.240.230.68-0.22-0.590.860.51-0.010.89-0.57
-0.230.9-0.80.940.640.90.12-0.310.77-0.460.61-0.49-0.30.440.66-0.42-0.330.35-0.69-0.310.440.510.710.54-0.71
0.030.61-0.780.610.080.61-0.02-0.840.78-0.020.14-0.65-0.380.010.15-0.68-0.53-0.14-0.550.06-0.05-0.010.710.2-0.58
-0.370.49-0.280.510.640.490.030.070.25-0.760.79-0.04-0.170.760.80.060.30.53-0.1-0.50.750.890.540.2-0.66
0.21-0.580.7-0.59-0.38-0.580.150.3-0.70.53-0.540.530.48-0.42-0.650.52-0.13-0.140.690.25-0.42-0.57-0.71-0.58-0.66
Click cells to compare fundamentals

Bone Biologics Account Relationship Matchups

Bone Biologics fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding12.2K12.1K18.9K47.6K263.1K250.0K
Total Assets30.8K0.06.7M8.5M3.7M2.3M
Net Debt11.3M11.7M(6.7M)(7.5M)(3.0M)(2.9M)
Cash24.1K0.06.7M7.5M3.0M2.0M
Cash And Short Term Investments955.4K24.1K6.7M7.5M3.0M2.1M
Liabilities And Stockholders Equity30.8K13.7M6.7M8.5M3.7M3.5M
Total Current Assets30.8K0.06.7M8.5M3.7M2.3M
Other Current Liab535.6K1.0M(99.9K)2.5M110.1K104.6K
Total Current Liabilities578.4K13.7M99.9K2.5M831.4K789.8K
Total Stockholder Equity(11.9M)(13.7M)6.6M5.9M2.9M3.1M
Retained Earnings(67.0M)(68.9M)(70.5M)(72.0M)(80.9M)(76.9M)
Total Liab11.9M13.7M99.9K2.5M831.4K789.8K
Short Long Term Debt Total8.2M9M11.3M11.7M13.5M8.3M
Other Current Assets105.2K85.3K6.7K956.9K711.2K746.8K
Accounts Payable42.9K465.4K99.9K888.46360.7K202.9K
Non Current Liabilities Total8.2M0.011.3M12.2M99.9K888.46
Net Invested Capital(547.6K)(2.0M)6.6M5.9M2.9M2.1M
Net Working Capital(547.6K)(13.7M)6.6M5.9M2.9M3.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.